Development of a cell-based assay measuring the activation of FcγRIIa for the characterization of therapeutic monoclonal antibodies

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Tada, Minoru ^a   Ishii Watabe, Akiko ^a   Suzuki, Takuo ^a   Kawasaki, Nana ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; FC RECEPTOR IIA; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2 ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY EGFR; PANITUMUMAB; PROTEIN VARIANT; RITUXIMAB; UNCLASSIFIED DRUG; FC RECEPTOR;

ANTIBODY AFFINITY; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BIOENGINEERING; CELL ASSAY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RECEPTOR BINDING; DRUG SCREENING; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN EXPRESSION; BIOASSAY; CELL LINE; FLOW CYTOMETRY; JURKAT CELL LINE; METABOLISM; PROCEDURES;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BIOLOGICAL ASSAY; CELL LINE; FLOW CYTOMETRY; HUMANS; JURKAT CELLS; RECEPTORS, IGG;

EID: 84899680868     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095787     Document Type: Article

References (49)

1. Alderson KL, Sondel PM (2011) Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity. J Biomed Biotechnol 2011: 379123.
2. Scott AM, Allison JP, Wolchok JD (2012) Monoclonal antibodies in cancer therapy. Cancer Immun 12: 14.
3. Weiner LM, Surana R, Wang S (2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 10: 317-327.
4. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, et al. (2006) Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 103: 4005-4010.
5. Mimoto F, Igawa T, Kuramochi T, Katada H, Kadono S, et al. (2013) Novel asymmetrically engineered antibody Fc variant with superior FcgammaR binding affinity and specificity compared with afucosylated Fc variant. MAbs 5: 229-236.
6. Richards JO, Karki S, Lazar GA, Chen H, Dang W, et al. (2008) Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther 7: 2517-2527.
7. Strohl WR (2009) Optimization of Fc-mediated effector functions of monoclonal antibodies. Curr Opin Biotechnol 20: 685-691.
8. Ferrara C, Brunker P, Suter T, Moser S, Puntener U, et al. (2006) Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II. Biotechnol Bioeng 93: 851-861.
9. Davies J, Jiang L, Pan LZ, LaBarre MJ, Anderson D, et al. (2001) Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. Biotechnol Bioeng 74: 288-294. (Pubitemid 32678662)
10. Satoh M, Iida S, Shitara K (2006) Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opin Biol Ther 6: 1161-1173. (Pubitemid 44714143)
11. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, et al. (2002) Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 277: 26733-26740. (Pubitemid 34951677)
12. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, et al. (2003) The absence of fucose but not the presence of galactose or bisecting N-Development acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 278: 3466-3473. (Pubitemid 36801263)
13. Zhou Q, Shankara S, Roy A, Qiu H, Estes S, et al. (2008) Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function. Biotechnol Bioeng 99: 652-665. (Pubitemid 351158263)
14. Subramaniam JM, Whiteside G, McKeage K, Croxtall JC (2012) Mogamulizumab: first global approval. Drugs 72: 1293-1298.
15. Traynor K (2013) Obinutuzumab approved for CLL: Monoclonal antibody product is first FDA-approved breakthrough therapy. Am J Health Syst Pharm 70: 2162.
16. Desjarlais JR, Lazar GA, Zhukovsky EA, Chu SY (2007) Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discov Today 12: 898-910. (Pubitemid 350052671)
17. Nimmerjahn F, Ravetch JV (2008) Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8: 34-47.
18. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, et al. (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99: 754-758. (Pubitemid 34525533)
19. Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21: 3940-3947.
20. Miller AS, Tejada ML, Gazzano-Santoro H (2012) Development of an ELISA based bridging assay as a surrogate measure of ADCC. J Immunol Methods 385: 45-50.
21. Parekh BS, Berger E, Sibley S, Cahya S, Xiao L, et al. (2012) Development and validation of an antibody-dependent cell-mediated cytotoxicity-reporter gene assay. MAbs 4: 310-318.
22. Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, et al. (2007) FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 25: 3712-3718. (Pubitemid 47372612)
23. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, et al. (2009) Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 113: 3716-3725.
24. Derer S, Glorius P, Schlaeth M, Lohse S, Klausz K, et al. (2014) Increasing FccRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity. MAbs 6: 10-22.
25. Nagarajan S, Venkiteswaran K, Anderson M, Sayed U, Zhu C, et al. (2000) Cell-specific, activation-dependent regulation of neutrophil CD32A ligand-binding function. Blood 95: 1069-1077. (Pubitemid 30062733)
26. Tsuboi N, Asano K, Lauterbach M, Mayadas TN (2008) Human neutrophil Fcgamma receptors initiate and play specialized nonredundant roles in antibody-mediated inflammatory diseases. Immunity 28: 833-846.
27. Schneider-Merck T, Lammerts van Bueren JJ, Berger S, Rossen K, van Berkel PH, et al. (2010) Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol 184: 512-520.
28. Tada M, Ishii-Watabe A, Maekawa K, Fukushima-Uesaka H, Kurose K, et al. (2012) Genetic polymorphisms of FCGR2A encoding Fcgamma receptor IIa in a Japanese population and functional analysis of the L273P variant. Immunogenetics 64: 869-877.
29. Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, et al. (2010) Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol 184: 1968-1976.
30. Heider KH, Kiefer K, Zenz T, Volden M, Stilgenbauer S, et al. (2011) A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies. Blood 118: 4159-4168.
31. Myszka DG (1999) Improving biosensor analysis. J Mol Recognit 12: 279-284.
32. Xu D, Alegre ML, Varga SS, Rothermel AL, Collins AM, et al. (2000) In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol 200: 16-26. (Pubitemid 30170076)
33. Bertolotti-Ciarlet A, Wang W, Lownes R, Pristatsky P, Fang Y, et al. (2009) Impact of methionine oxidation on the binding of human IgG1 to Fc Rn and Fc gamma receptors. Mol Immunol 46: 1878-1882.
34. Pan H, Chen K, Chu L, Kinderman F, Apostol I, et al. (2009) Methionine oxidation in human IgG2 Fc decreases binding affinities to protein A and FcRn. Protein Sci 18: 424-433.
35. Wang W, Vlasak J, Li Y, Pristatsky P, Fang Y, et al. (2011) Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies. Mol Immunol 48: 860-866.
36. Bretaudeau L, Bonnaudet V (2011) ADCC potency assay: increased standardization with modified lymphocytes. BMC Proc 5 Suppl 8: P63.
37. Schnueriger A, Grau R, Sondermann P, Schreitmueller T, Marti S, et al. (2011) Development of a quantitative, cell-line based assay to measure ADCC activity mediated by therapeutic antibodies. Mol Immunol 48: 1512-1517.
38. Nelson DL, Kurman CC, Serbousek DE (2001) 51Cr release assay of antibody-dependent cell-mediated cytotoxicity (ADCC). Curr Protoc Immunol Chapter 7: Unit 7 27.
39. Carter PJ (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6: 343-357.
40. Brennan FR, Morton LD, Spindeldreher S, Kiessling A, Allenspach R, et al. (2010) Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. MAbs 2: 233-255.
41. Bugelski PJ, Achuthanandam R, Capocasale RJ, Treacy G, Bouman-Thio E (2009) Monoclonal antibody-induced cytokine-release syndrome. Expert Rev Clin Immunol 5: 499-521.
42. Wilde MI, Goa KL (1996) Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Drugs 51: 865-894.
43. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, et al. (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355: 1018-1028. (Pubitemid 44343545)
44. Tax WJ, Tamboer WP, Jacobs CW, Frenken LA, Koene RA (1997) Role of polymorphic Fc receptor Fc gammaRIIa in cytokine release and adverse effects of murine IgG1 anti-CD3/T cell receptor antibody (WT31). Transplantation 63: 106-112. (Pubitemid 27036699)
45. Jonsson F, Mancardi DA, Zhao W, Kita Y, Iannascoli B, et al. (2012) Human FcgammaRIIA induces anaphylactic and allergic reactions. Blood 119: 2533-2544.
46. Kawakami T (2012) Human FcgammaRIIA at center stage. Blood 119: 2432-2433.
47. Cleland JL, Powell MF, Shire SJ (1993) The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit Rev Ther Drug Carrier Syst 10: 307-377. (Pubitemid 24021947)
48. Vlasak J, Ionescu R (2008) Heterogeneity of monoclonal antibodies revealed by charge-sensitive methods. Curr Pharm Biotechnol 9: 468-481.
49. Liu D, Ren D, Huang H, Dankberg J, Rosenfeld R, et al. (2008) Structure and stability changes of human IgG1 Fc as a consequence of methionine oxidation. Biochemistry 47: 5088-5100. (Pubitemid 351620747)